Duration-Dependent Effects of Water-Only Fasting on Blood Lipids: A Systematic Review, Meta-Analysis, and Threshold Meta-Regression

Why It Matters

The findings reveal that fasting duration critically shapes lipid responses, informing clinicians about potential cardiovascular risks or benefits when recommending water‑only fasting protocols.

Key Takeaways

• HDL declines after three days of water‑only fasting
• LDL and total cholesterol rise early, plateau around day 5‑10
• Triglycerides drop in short fasts, rise in longer fasts
• VLDL changes are small and inconsistent across studies
• Publication bias detected for LDL and total cholesterol results

Pulse Analysis

Water‑only fasting forces the body to shift from glucose to fat as its primary fuel. Within the first 24‑48 hours glycogen stores are exhausted, prompting massive lipolysis and a surge of free fatty acids that the liver converts into ketone bodies. This metabolic pivot explains the early rise in low‑density lipoprotein (LDL) and total cholesterol observed in the meta‑analysis, as hepatic very‑low‑density lipoprotein (VLDL) production accelerates to transport excess fatty acids. Simultaneously, high‑density lipoprotein (HDL) synthesis slows, leading to modest declines after about three days.

The systematic review pooled 32 human trials, covering fasts from one to 17 days and more than 600 participants. 5, LDL peaked near day 10, and total cholesterol stabilized after day 5. Threshold meta‑regression, a technique rarely applied to nutrition data, allowed these nonlinear patterns to emerge despite high heterogeneity. However, funnel‑plot asymmetry suggests small‑study bias for LDL and total cholesterol.

For clinicians, the findings imply that short‑term water fasting (≤3 days) may modestly improve triglycerides but can depress HDL, while prolonged fasts (>3 days) risk transient elevations in LDL and total cholesterol—potentially problematic for patients with existing dyslipidemia. Because the lipid shifts appear reversible after refeeding, monitoring is advisable rather than outright avoidance. Future research should prioritize randomized controlled trials with standardized refeeding, longer follow‑up, and mechanistic markers such as apolipoprotein AI and FGF21 to determine whether these acute changes translate into lasting cardiovascular risk or benefit. Longitudinal data will clarify the net impact on heart disease risk.